You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HPV Type

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Head and Neck Squamous Cell Carcinoma Trial in Seoul (GX-188E+GX-I7+Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
May 18, 2022

Adenocarcinoma of the Uterine Cervix and HPV

Not yet recruiting
  • Adenocarcinoma of the Uterine Cervix
  • Conization and/or Hysterectomy
  • (no location specified)
May 23, 2022

Oral HPV Infection in Patients Who Are Positive to the PAP-test

Recruiting
  • HPV Infection
    • Catania, Italy
      AOU Policlinico G. Rodolico
    Jul 13, 2023

    Vulvar Diseases, HPV Infection, Vulvar HSIL Trial in Cleveland, Mayfield Heights (Artesunate ointment, Placebo ointment)

    Not yet recruiting
    • Vulvar Diseases
    • +12 more
    • Artesunate ointment
    • Placebo ointment
    • Cleveland, Ohio
    • +2 more
    Oct 4, 2023

    Condylomata Acuminata Trial (low dosage HPV Vaccine, medium dosage HPV Vaccine, high dosage HPV Vaccine)

    Completed
    • Condylomata Acuminata
    • low dosage HPV Vaccine
    • +3 more
    • (no location specified)
    May 23, 2022

    Cervical Carcinoma, Human Papillomavirus Infection Trial in Liberia (Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis

    Enrolling by invitation
    • Cervical Carcinoma
    • Human Papillomavirus Infection
    • Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
    • +3 more
    • Liberia, Guanacaste, Costa Rica
      Agencia Costarricense de Investigaciones Biomédicas - Fundación
    Aug 11, 2022

    After Whole Vaccination Shcedule With Recombination Quadrivalent

    Not yet recruiting
    • HPV Infections
    • +6 more
      • (no location specified)
      May 7, 2022

      Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles Trial in Shaoxing, Wuyi

      Active, not recruiting
      • Human Papilloma Virus Infection Type 16
      • +4 more
      • HPV+MMR（0d），HPV（6m）
      • +2 more
      • Shaoxing, Zhejiang, China
      • +1 more
      Mar 14, 2022

      Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal HPV-Positive Squamous Cell Carcinoma

      Recruiting
      • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
      • Oropharyngeal HPV-Positive Squamous Cell Carcinoma
      • Radiation Therapy
      • Atlanta, Georgia
      • +1 more
      Jun 7, 2022

      Recurrent Human Papillomavirus Type 16 Associated Cancer Trial in Birmingham, Baltimore (HPV 16 TA-CIN)

      Withdrawn
      • Recurrent Human Papillomavirus Type 16 Associated Cancer
      • HPV 16 TA-CIN
      • Birmingham, Alabama
      • +1 more
      Nov 29, 2022

      Condylomata Acuminata Trial (low dosage HPV Vaccine(1:1), low dosage HPV Vaccine(1:2), high dosage HPV Vaccine(1:1))

      Active, not recruiting
      • Condylomata Acuminata
      • low dosage HPV Vaccine(1:1)
      • +3 more
      • (no location specified)
      Feb 10, 2022

      Cervical Intraepithelial Neoplasia Grade 2/3, Tumor Cervix, Carcinoma in Situ Trial in Milan (Self-Collecting Devices, In Vitro

      Completed
      • Cervical Intraepithelial Neoplasia Grade 2/3
      • +5 more
      • Self-Collecting Devices
      • In Vitro Diagnostic Assays
      • Dublin, Ireland
      • +5 more
      Jan 5, 2023

      QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys

      Not yet recruiting
      • HPV-Related Carcinoma
      • Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine
      • (no location specified)
      Jun 3, 2021

      Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in

      Not yet recruiting
      • Head and Neck Cancer
      • +8 more
      • Tumor and HLA Profiling
      • (no location specified)
      Mar 31, 2023

      Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata Trial in Nanjing, Chengdu (Nonavalent HPV vaccine,

      Active, not recruiting
      • Cervical Intraepithelial Neoplasia
      • +2 more
      • Nonavalent HPV vaccine
      • Bivalent HPV vaccine
      • Nanjing, Jiangsu, China
      • +1 more
      Feb 10, 2022

      HPV Infections, Cervical Cancer, Vulvar Cancer Trial in Hangzhou (9-valent HPV vaccine)

      Recruiting
      • HPV Infections
      • +14 more
      • 9-valent HPV vaccine
      • Hangzhou, China
        Huakun Lv
      Feb 23, 2022

      HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer Trial in Mianyang (2-doses Group among 9-14 years, 3-doses Group among

      Recruiting
      • HPV Infections
      • +6 more
      • 2-doses Group among 9-14 years
      • +2 more
      • Mianyang, Sichuan, China
        Center for Disease Control and Prevention
      Feb 23, 2022

      Cervical Cancer, Genital Warts Trial (Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine, Matching Placebo)

      Active, not recruiting
      Has Results
      • Cervical Cancer
      • Genital Warts
      • Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
      • Matching Placebo
      • (no location specified)
      Aug 22, 2022

      Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III Trial

      Recruiting
      • Human Papillomavirus Type 16
      • +2 more
      • Baltimore, Maryland
        Johns Hopkins University
      Jul 2, 2021

      Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls

      Completed
      • HPV Vaccine
      • +2 more
      • Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine
      • Thika, Kiambu, Kenya
        Partners in Health Research and Development
      Jan 12, 2021

      Condylomata Acuminata, Cervical Cancer Trial in Nanjing (HPV Vaccine,135µg/0.5ml, HPV Vaccine,270µg/1.0ml)

      Completed
      • Condylomata Acuminata
      • Cervical Cancer
      • HPV Vaccine,135μg/0.5ml
      • HPV Vaccine,270μg/1.0ml
      • Nanjing, Jiangsu, China
        Jiangsu Provincial Centre for Disease Control and Prevention
      Apr 7, 2021

      Uterine Cervical Tumors, Uterine Cervical Cancer, Tumors, Squamous Cell Trial in Seattle (BD SurePath Plus Pap test, BD SurePath

      Terminated
      Has Results
      • Uterine Cervical Neoplasms
      • +6 more
      • BD SurePath Plus Pap test
      • +3 more
      • Seattle, Washington
        Seattle Women's: Health, Research, Gynecology
      Apr 12, 2021

      Condylomata Acuminata, Cervical Cancer Trial in Nanjing (HPV Vaccine,270µg/1.0ml, Placebo)

      Completed
      • Condylomata Acuminata
      • Cervical Cancer
      • HPV Vaccine,270μg/1.0ml
      • Placebo
      • Nanjing, Jiangsu, China
        Jiangsu Provincial Centre for Disease Control and Prevention
      Apr 7, 2021

      The Durability of Protection and Immuno-persistence Study

      Recruiting
      • Cervical Intraepithelial Neoplasia
      • +4 more
      • Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
      • Zhengzhou, Henan, China
        Henan Cancer Hospital
      Sep 14, 2021

      Immunization, Efficacy, Human Papilloma Virus Trial in Galveston (9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3

      Recruiting
      • Immunization
      • +2 more
      • 9-valent HPV vaccine, 2 dose efficacy
      • 9-valent HPV vaccine, 3 doses standard timing
      • Galveston, Texas
        University of Texas Medical Branch
      Jan 30, 2023